Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ADAMTS5 | Q9UNA0 | 6/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688455 | 1.00 | ALDH1A1 (0.37) | ALDH1A1ADAMTS5ADAM17TSHRCRBN | |
| SCHEMBL29688685 | 1.00 | ALDH1A1 (0.37) | ALDH1A1ADAMTS5ADAM17TSHRCRBN | |
| SCHEMBL20134750 | 1.00 | ALDH1A1 (0.37) | ALDH1A1ADAMTS5ADAM17TSHRCRBN | |
| SCHEMBL20134751 | 1.00 | ALDH1A1 (0.37) | ALDH1A1ADAMTS5ADAM17TSHRCRBN | |
| SCHEMBL29688589 | 1.00 | ALDH1A1 (0.37) | ALDH1A1ADAMTS5ADAM17TSHRCRBN | |
| SCHEMBL29688625 | 0.93 | ALDH1A1 (0.36) | ALDH1A1ADAMTS5ADAM17CRBNHPGD | |
| SCHEMBL20135433 | 0.93 | ALDH1A1 (0.36) | ALDH1A1ADAMTS5ADAM17CRBNHPGD | |
| SCHEMBL20135123 | 0.91 | LMNA (0.44) | ALDH1A1ADAMTS5ADAM17TSHRLMNA | |
| SCHEMBL20135127 | 0.91 | LMNA (0.44) | ALDH1A1ADAMTS5ADAM17TSHRLMNA | |
| SCHEMBL20135401 | 0.91 | LMNA (0.44) | ALDH1A1ADAMTS5ADAM17TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3321256-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077787-A1 | NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE | MMP9, MMP10, MMP1 | ALDH1A1 584/4885ADAMTS5 23/4885ADAM17 36/4885 |
| US-10407408-B2 | Imide derivatives and use thereof as medicine | MMP9, MMP2, MMP1 | ALDH1A1 610/4885ADAMTS5 25/4885ADAM17 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.